D B Mendel

Summary

Affiliation: Preclinical Research and Exploratory Development
Country: USA

Publications

  1. ncbi Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
    D B Mendel
    SUGEN, Inc, South San Francisco, CA 94080, USA
    Anticancer Drug Des 15:29-41. 2000
  2. ncbi The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function
    D B Mendel
    SUGEN, Inc, South San Francisco, California 94080, USA
    Clin Cancer Res 6:4848-58. 2000
  3. ncbi In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship
    Dirk B Mendel
    Preclinical Research and Exploratory Development, SUGEN, Inc, South San Francisco, California 94080, USA
    Clin Cancer Res 9:327-37. 2003
  4. ncbi High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo
    J G Christensen
    SUGEN, Inc, 230 East Grand Avenue, South San Francisco, CA 94080, USA
    Clin Cancer Res 7:4230-8. 2001
  5. pmc Conversion of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine to cidofovir by an intracellular cyclic CMP phosphodiesterase
    D B Mendel
    Gilead Sciences, Inc, Foster City, California 94404, USA
    Antimicrob Agents Chemother 41:641-6. 1997
  6. ncbi CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice
    Xiaohua Xin
    Translational Sciences, Chiron Corporation, Emeryville, California, USA
    Clin Cancer Res 12:4908-15. 2006
  7. ncbi SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity
    Shem Patyna
    Pfizer Global Research and Development, 10777 Science Center Drive, San Diego, CA 92024, USA
    Mol Cancer Ther 5:1774-82. 2006
  8. ncbi Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248
    Olga Potapova
    Cureline, Inc, 393 East Grand Avenue, Suite I, South San Francisco, CA 94080, USA
    Mol Cancer Ther 5:1280-9. 2006
  9. ncbi A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo
    James G Christensen
    Preclinical Research and Exploratory Development, SUGEN, Inc, South San Francisco, CA 94080, USA
    Cancer Res 63:7345-55. 2003
  10. ncbi Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans
    Katherine G Moss
    Department of Preclinical Research and Exploratory Development, SUGEN Inc, South San Francisco, CA, USA
    J Pharmacol Exp Ther 307:476-80. 2003

Collaborators

  • J G Christensen
  • G Li
  • S Weitman
  • B D Smolich
  • Tinya J Abrams
  • L Liu
  • T Cihlar
  • Xueyan Wang
  • Nancy K Pryer
  • Suzanne Trudel
  • Olga Potapova
  • Li Sun
  • Lesley J Murray
  • A Douglas Laird
  • Julie M Cherrington
  • Katherine G Moss
  • Xiaohua Xin
  • Cheryl A London
  • Qing Zhu
  • Shem Patyna
  • Evelyn N Garrett
  • Paul W Hollenbach
  • Narmada Shenoy
  • May B Chien
  • Gerald McMahon
  • Albert T Liao
  • Millicent G Embry
  • Juthamas Sukbuntherng
  • Maren Grazzini
  • Huiping Guan
  • Montesa B Patawaran
  • Chris Liang
  • Bahija Jallal
  • Katherine G Rendahl
  • Debbie E Swinarski
  • Wei Zhu Zhong
  • Yoko A Oei
  • Joshua O Haznedar
  • Yan Tang
  • Yoko Oei
  • Amy J Weiner
  • Carla C Heise
  • Stefan Vasile
  • Dana Hu-Lowe
  • Sharon L Aukerman
  • Anne Marie O'Farrell
  • Tomas Vojkovsky
  • Jeffrey Chen
  • Cheng Y Yang
  • Robert A Blake
  • Sue Downing
  • Guy C Toner
  • Cynthia Kollias-Baker
  • Mona Rosenberg
  • Gerald Post
  • Joseph Boucher
  • Regina Zadovoskaya
  • Martin A Broome
  • Alison L Hannah
  • Sharianne G Louie
  • Jeremy Carver
  • Kimberly Smith

Detail Information

Publications15

  1. ncbi Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
    D B Mendel
    SUGEN, Inc, South San Francisco, CA 94080, USA
    Anticancer Drug Des 15:29-41. 2000
    ..Its biochemical, biological and pharmacological properties are reviewed and clinical implications discussed...
  2. ncbi The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function
    D B Mendel
    SUGEN, Inc, South San Francisco, California 94080, USA
    Clin Cancer Res 6:4848-58. 2000
    ..The long-lasting inhibitory activity of SU5416 in vitro is consistent with the finding that SU5416 has demonstrated evidence of biological activity in clinical studies when administered twice a week despite a short plasma half-life...
  3. ncbi In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship
    Dirk B Mendel
    Preclinical Research and Exploratory Development, SUGEN, Inc, South San Francisco, California 94080, USA
    Clin Cancer Res 9:327-37. 2003
    ..The pharmacokinetic/pharmacodynamic relationship established for SU11248 in these preclinical studies has aided in the design, selection, and evaluation of dosing regimens being tested in human trials...
  4. ncbi High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo
    J G Christensen
    SUGEN, Inc, 230 East Grand Avenue, South San Francisco, CA 94080, USA
    Clin Cancer Res 7:4230-8. 2001
    ..The potential clinical implications of this observation are discussed...
  5. pmc Conversion of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine to cidofovir by an intracellular cyclic CMP phosphodiesterase
    D B Mendel
    Gilead Sciences, Inc, Foster City, California 94404, USA
    Antimicrob Agents Chemother 41:641-6. 1997
    ..Importantly, hydrolysis of cHPMPC is not diminished in cells infected with HCMV...
  6. ncbi CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice
    Xiaohua Xin
    Translational Sciences, Chiron Corporation, Emeryville, California, USA
    Clin Cancer Res 12:4908-15. 2006
    ..This study assesses the antimyeloma activity of CHIR-258, a small-molecule inhibitor of multiple receptor tyrosine kinases that is currently in phase I trials, in a newly developed FGFR3-driven preclinical MM animal model...
  7. ncbi SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity
    Shem Patyna
    Pfizer Global Research and Development, 10777 Science Center Drive, San Diego, CA 92024, USA
    Mol Cancer Ther 5:1774-82. 2006
    ..These data support the ongoing phase I clinical evaluation of SU14813 in advanced malignancies...
  8. ncbi Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248
    Olga Potapova
    Cureline, Inc, 393 East Grand Avenue, Suite I, South San Francisco, CA 94080, USA
    Mol Cancer Ther 5:1280-9. 2006
    ....
  9. ncbi A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo
    James G Christensen
    Preclinical Research and Exploratory Development, SUGEN, Inc, South San Francisco, CA 94080, USA
    Cancer Res 63:7345-55. 2003
    ..Collectively, these results demonstrate the feasibility of selectively targeting c-Met with ATP-competitive small-molecules and suggest the therapeutic potential of targeting c-Met in human cancers...
  10. ncbi Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans
    Katherine G Moss
    Department of Preclinical Research and Exploratory Development, SUGEN Inc, South San Francisco, CA, USA
    J Pharmacol Exp Ther 307:476-80. 2003
    ..These data demonstrate that hair pigmentation can serve as a dose-dependent, dynamic, biological readout for KIT inhibition in mice, and, apparently, in humans...
  11. ncbi Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies
    Cheryl A London
    School of Veterinary Medicine, University of California, Davis, Davis, California 95616, USA
    Clin Cancer Res 9:2755-68. 2003
    ....
  12. ncbi Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tu
    A Douglas Laird
    Preclinical Research and Exploratory Development, SUGEN, Inc, South San Francisco, California 94080, USA
    Mol Cancer Ther 2:461-9. 2003
    ..These data demonstrate that STAT3 (Y705) and FAK (Y861) phosphoepitopes are SFK-dependent in tumor cells and reveal a requirement for SFK function in tumor cell proliferation and vascular permeability...
  13. ncbi Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors
    Albert T Liao
    Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California at Davis, CA 95616, USA
    Blood 100:585-93. 2002
    ..Because the concentrations of drug necessary for receptor inhibition are readily achievable and nontoxic in vivo, these compounds may be useful in the treatment of spontaneous cancers expressing Kit mutations...
  14. ncbi SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice
    A Douglas Laird
    SUGEN, Inc, Preclinical Research and Translational Medicine, South San Francisco, California 94080, USA
    FASEB J 16:681-90. 2002
    ..These data demonstrate that SU6668-induced inhibition of angiogenic receptor tyrosine kinase activity in vivo is associated with rapid vessel killing in tumors, leading to broad and potent antitumor effects...
  15. pmc Novel robust hepatitis C virus mouse efficacy model
    Qing Zhu
    Department of Pharmacology, Novartis Vaccines and Diagnostics, Chiron Corportion, Emeryville, CA 94608
    Antimicrob Agents Chemother 50:3260-8. 2006
    ..This robust mouse efficacy model provides a powerful tool for rapid evaluation of potential anti-HCV compounds in vivo as part of aggressive drug discovery efforts...